These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 14585237)

  • 21. Management of ascites in patients with end-stage liver disease.
    Saadeh S; Davis GL
    Rev Gastroenterol Disord; 2004; 4(4):175-85. PubMed ID: 15580152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians.
    Gallo A; Dedionigi C; Civitelli C; Panzeri A; Corradi C; Squizzato A
    J Transl Int Med; 2020 Dec; 8(4):220-236. PubMed ID: 33511049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ascites: tips on diagnosis and management.
    Al Mofleh IA; Al Rashed RS
    Saudi J Gastroenterol; 1996 May; 2(2):80-6. PubMed ID: 19864832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis.
    Allegretti AS; Ortiz G; Cui J; Wenger J; Bhan I; Chung RT; Thadhani RI; Irani Z
    Am J Kidney Dis; 2016 Sep; 68(3):381-91. PubMed ID: 26994685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Refractory ascites and dilutional hyponatremia: current management and new aquaretics].
    Torre Delgadillo A
    Rev Gastroenterol Mex; 2005; 70(3):299-311. PubMed ID: 17063787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
    Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
    Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of cirrhotic ascites: physiological basis of diuretic action.
    Rosner MH; Gupta R; Ellison D; Okusa MD
    Eur J Intern Med; 2006 Jan; 17(1):8-19. PubMed ID: 16378879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacotherapy of ascites associated with cirrhosis.
    Ginès P; Arrovo V; Rodés J
    Drugs; 1992 Mar; 43(3):316-32. PubMed ID: 1374317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.
    Tan HK; James PD; Wong F
    Dig Dis Sci; 2016 Oct; 61(10):3084-3092. PubMed ID: 27048451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.
    Salerno F; Guevara M; Bernardi M; Moreau R; Wong F; Angeli P; Garcia-Tsao G; Lee SS
    Liver Int; 2010 Aug; 30(7):937-47. PubMed ID: 20492521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ascites in cirrhosis: a review of management and complications.
    Kuiper JJ; van Buuren HR; de Man RA
    Neth J Med; 2007 Sep; 65(8):283-8. PubMed ID: 17890787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites.
    Shen NT; Schneider Y; Congly SE; Rosenblatt RE; Namn Y; Fortune BE; Jesudian A; Brown RS
    Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1503-1510.e3. PubMed ID: 29609068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refractory Ascites: Pathogenesis, Clinical Impact, and Management.
    Siqueira F; Kelly T; Saab S
    Gastroenterol Hepatol (N Y); 2009 Sep; 5(9):647-656. PubMed ID: 37967427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo.
    Fernández-Esparrach G; Guevara M; Sort P; Pardo A; Jiménez W; Ginès P; Planas R; Lebrec D; Geuvel A; Elewaut A; Adler M; Arroyo V
    J Hepatol; 1997 Mar; 26(3):614-20. PubMed ID: 9075669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites.
    Garcia-Tsao G
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jul; 3(7):380-9. PubMed ID: 16819501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of ascites: old and new remedies.
    Inturri P; Graziotto A; Rossaro L
    Dig Dis; 1996; 14(3):145-56. PubMed ID: 8861522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of refractory ascites.
    Velamati PG; Herlong HF
    Curr Treat Options Gastroenterol; 2006; 9(6):530-7. PubMed ID: 17081486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment options for cirrhotic ascites.
    Wilkinson SP
    Eur J Gastroenterol Hepatol; 1998 Jan; 10(1):1-3. PubMed ID: 9565461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of ascites and hepatorenal syndrome.
    Piano S; Tonon M; Angeli P
    Hepatol Int; 2018 Feb; 12(Suppl 1):122-134. PubMed ID: 28836115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between increased colloid osmotic pressure and the resolution of refractory ascites after transjugular intrahepatic portosystemic shunt.
    Schiano TD; Black M; Hills C; Ter H; Bellary S; Miller LS
    South Med J; 2000 Mar; 93(3):305-9. PubMed ID: 10728519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.